{"id":331482,"date":"2026-10-29T11:42:26","date_gmt":"2026-10-29T06:12:26","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=331482"},"modified":"2026-10-29T11:42:26","modified_gmt":"2026-10-29T06:12:26","slug":"midcap-uti-mutual-fund-stocks-to-watch-multibagger-potential","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/midcap-uti-mutual-fund-stocks-to-watch-multibagger-potential\/","title":{"rendered":"4 Midcap UTI Mutual Fund Stocks to Watch for Future Multibagger Potential: Dixon, Ajanta Pharma, Astral and Dr Lal PathLabs"},"content":{"rendered":"

Dixon Rs 11,400. Ajanta Pharma Rs 3,459.80. Astral Rs 1,360.60. Dr Lal PathLabs Rs 1,922.30. Market caps from Rs 32,757 crore to Rs 77,049 crore. Data as of 28 Oct 2026.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Dixon, Ajanta Pharma, Astral and Dr Lal PathLabs are the 4 picks in this UTI mutual fund stocks watchlist, with market caps between Rs 32,757 crore and Rs 77,049 crore. Dixon stands out for the highest return on equity at 30.76%, while Ajanta Pharma offers the biggest five-year price gain at 125.31%. PE ratios run from 37.01 to 64.16, so compare each one with its industry PE before investing. All figures are as of 28 October 2026.<\/p>\n<\/p><\/div>\n

UTI mutual fund stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Dixon, Ajanta Pharma, Astral and Dr Lal PathLabs meet that test, with market caps from Rs 32,757 crore to Rs 77,049 crore and Dixon offering the highest return on equity at 30.76%. Each of these companies has a market capitalisation between Rs 30,000 crore and Rs 1,00,000 crore and UTI Mutual Fund or one of its schemes listed among its top domestic institutional holders, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, and net profit rose in FY26 and in the latest quarter.<\/p>\n

This list covers companies with a market capitalisation between Rs 30,000 crore and Rs 1,00,000 crore and UTI Mutual Fund or one of its schemes listed among its top domestic institutional holders, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, rising profit in FY26 and the latest quarter, and complete, verifiable financials, ranked by market capitalisation. Each company has a market cap between Rs 30,000 crore and Rs 1 lakh crore. Investors screening UTI mutual fund stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 28 October 2026 and are drawn from NSE and BSE data and company filings.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n